DELTA TEEN is a phase 3 clinical trial by LEO Pharma that evaluated Anzupgo® (delgocitinib) 20mg/g cream for adolescents with moderate-to-severe chronic hand eczema (CHE). The trial demonstrated positive results for patients whose condition is not adequately managed with topical corticosteroids.
The 16-week, randomized, double-blind study evaluated Anzupgo’s effectiveness in patients aged 12 to 17 years with moderate-to-severe CHE. Success was measured using the Investigator’s Global Assessment for CHE Treatment Success (IGA-CHE TS), requiring participants to achieve a score of 0 (clear) or 1 (almost clear) with at least a two-step improvement from baseline.
Results revealed statistically significant improvements in CHE symptoms compared to the vehicle control cream. Both primary and secondary endpoints were met, aligning with the safety profile observed in earlier trials, further strengthening the drug’s potential as a treatment option for adolescent patients.
Anzupgo, a topical pan-Janus kinase (JAK) inhibitor, works by inhibiting the activation of the JAK-STAT signaling pathway, which plays a key role in the pathogenesis of CHE. This mechanism aims to reduce inflammation, restore skin barrier function, and improve overall symptomatology.
Professor Sonja Molin, Academic Dermatologist at Charité Universitätsmedizin Berlin and Adjunct Associate Professor of Dermatology at Queen’s University, and coordinating investigator, stated:
“Research on adolescents with CHE has revealed that the condition can considerably affect their quality of life, including psychosocial well-being, school performance, and leisure activities. These findings further our understanding of how moderate-to-severe CHE manifests in adolescents and how to support this underserved patient group.”
Anzupgo is currently approved for the treatment of moderate-to-severe CHE in adults in the European Union, United Kingdom, Switzerland, and the United Arab Emirates.
The trial’s success supports potential regulatory approval for adolescent use, addressing an important clinical need. Further research and review will clarify its impact on adolescent CHE treatment. Detailed DELTA TEEN results will be shared later through scientific presentations and publications.
Sources:
- LEO Pharma Achieves Positive DELTA TEEN Trial Results with Anzupgo® (delgocitinib) Cream in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE). (n.d.). [Press release]. https://www.leo-pharma.com/media-center/news/2025-delta-teen-topline-key-results
- Delgocitinib Could Close Gap in Adolescent CHE Treatment. (n.d.). Dermatology Times. https://www.dermatologytimes.com/view/delgocitinib-could-close-gap-in-adolescent-che-treatment
